Composition for inhibiting tumor cell proliferation by using epigallocatechin gallate and carboplatin

A technology of epigallocatechin and tumor cell proliferation, which is applied in the fields of medicine and genetic engineering, can solve the problems such as the report on the combined use of EGCG and carboplatin, etc., achieves abundant resources, reduces dosage and drug cost, and improves inhibition rate Effect

Inactive Publication Date: 2012-07-11
FUDAN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] So far, there is no report on the combined use of EGCG and carboplatin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for inhibiting tumor cell proliferation by using epigallocatechin gallate and carboplatin
  • Composition for inhibiting tumor cell proliferation by using epigallocatechin gallate and carboplatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Synergistic effect of EGCG and carboplatin

[0033] The combined use of EGCG and ten anti-liver cancer drugs has a synergistic effect, and the synergistic effect with carboplatin in SK-Hep1 cells is very significant. In this example, the combination effect of EGCG and carboplatin was further verified in cells such as HepG2 and Hep3B, and the results proved that the CI values ​​were all less than 1 within a certain concentration range, and the two drugs had a synergistic effect. The results showed that the combined use of EGCG and carboplatin can improve the antitumor effect of carboplatin.

[0034] Table 1

[0035] Carboplatin drug concentration (uM) EGCG drug concentration (uM) Carboplatin monotherapy inhibition rate (%) Carboplatin-EGCG combined inhibition rate (%) SMMMC7721 70 15 31.94 24.25 HepG2 50 15 75.84 68.67 QUR 13.5 10 41.2 35.48 SK-hep-1 16.8 20 32.29 43.41 YY1 80 20 55.24 46.42 ...

Embodiment 2

[0036] Example 2 EGCG has a synergistic effect with carboplatin

[0037] A fixed concentration of EGCG was administered in combination with carboplatin in ten hepatocellular carcinoma cell lines. The following King's formula Q value was used to evaluate the combination effect.

[0038] Q=Ea+b / (Ea+Eb-Ea×Eb)

[0039] Among them, Ea+b is the inhibition rate of combined drugs, and Ea and Eb are the inhibition rates of drug A and drug B respectively;

[0040] The numerator represents the actual measured combined inhibition rate of the two drugs, and the denominator is the expected combined inhibition rate.

[0041] The range of Q=0.85-1.15 means simple addition, the range of Q=1.15-2 means enhancement, Q>2 means obvious enhancement, Q<0.55-0.85 means antagonistic effect, and Q<0.55 means obvious antagonism.

[0042] The results show that EGCG and carboplatin have a certain synergistic effect in specific cell lines, indicating that EGCG can enhance the anti-tumor activity of ...

Embodiment 3

[0047] Example 3 EGCG can enhance carboplatin and reduce the dosage of carboplatin

[0048] In SK-Hep1 cells, 0.25, 0.5, 0.75 μM carboplatin was combined with 10, 20, 30, 40, 50 μM EGCG, respectively, and 0.25, 0.5, 0.75 μM carboplatin was combined with different concentrations of EGCG Can reach or even exceed the effect of 1 μM carboplatin alone. According to the statistical analysis of the software, the amount of carboplatin required to achieve half the inhibitory effect when used in combination with EGCG decreases with the increase of the amount of EGCG, and has a concentration gradient effect. The above experimental results show that the combined use of EGCG and carboplatin can effectively enhance the anti-tumor effect of carboplatin and reduce its dosage.

[0049]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention, belonging to the field of medicine and gene engineering, provides a composition for inhibiting tumor cell proliferation. The composition comprises epigallocatechin gallate and carboplatin as the active components and pharmaceutically necessary auxiliary materials, wherein the molar ratio of epigallocatechin gallate to carboplatin is 200:1-1:7. Experiments prove that by using the composition made from epigallocatechin gallate and carboplatin or combining epigallocatechin gallate while using carboplatin, the therapeutic effect of carboplatin for inhibiting tumor cell proliferation is significantly raised. According to the invention, the composition has no toxicity to nude rat liver and kidney basically, the resource of epigallocatechin gallate in the active components is abundant, and the price is low; and the composition raises the inhibition rate of tumors and simultaneously reducing the treatment cost for tumor patients.

Description

technical field [0001] The invention belongs to the fields of medicine and genetic engineering, and relates to a composition for inhibiting tumor cell proliferation, in particular to a composition for inhibiting tumor cell proliferation made of epigallocatechin gallate (EGCG) and carboplatin (CBP). Background technique [0002] Carboplatin Carboplatin was discovered by Clear et al. in 1980. It was first launched in the UK in 1986. It was approved by the US FDA in 1989 and its application was gradually promoted. my country approved the production of carboplatin powder and injection in 1990. [0003] Common name of carboplatin: carboplatin; Chinese aliases: carboplatin, carboplatin, platinum platinum; [0004] [0005] Foreign name: Carboplatin, Paraplatin, Carboplat, Ercar; English abbreviation: CBP, JM-8, CBDCA; chemical name: cis-1,1-cyclobutanedicarboxylic acid diaminoplatinum; molecular formula: C6H12N2O4Pt. [0006] Solid carboplatin is white crystalline powder, sl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/353A61K31/282A61P35/00
Inventor 余龙张明君刘祖龙朱恒锐唐丽莎
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products